MSB.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 02:10):

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland...

Stats
Today's Volume	12.95M
Average Volume	9.47M
Market Cap	907.18M
EPS	$0 ( 2024-02-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.43
ATR14	$0.00300 (0.33%)

Volume Correlation

Long: 0.06 (neutral)

Short: -0.12 (neutral)

Signal:(64.092) Neutral

Mesoblast Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mesoblast Ltd Correlation - Currency/Commodity

0.04
( neutral )

-0.30
( neutral )

0.00
( neutral )

0.38
( neutral )

Mesoblast Ltd Financials

Annual	2023
Revenue:	$7.50M
Gross Profit:	$-47.42M (-632.20 %)
EPS:	$-0.110

Q4	2023
Revenue:	$2.14M
Gross Profit:	$-13.28M (-620.90 %)
EPS:	$-0.0279

Q3	2023
Revenue:	$1.94M
Gross Profit:	$-11.37M (-586.54 %)
EPS:	$-0.0253

Q2	2023
Revenue:	$1.98M
Gross Profit:	$-13.60M (-686.72 %)
EPS:	$-0.0332

Financial Reports:

No articles found.

Mesoblast Ltd

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.